Barbanoj M J, Urbano G, Antonijoan R, Ballester M R, Valle M
Centre d'Investigació del Medicament, Institut de Recerca HSCSP, Servei de Farmacologia Clinica, Hospital de la Santa Creu i Sant Pau, and Departament de Farmacologia i Terapèutica (UAB), Barcelona, Spain.
Neuropsychobiology. 2007;55(3-4):203-12. doi: 10.1159/000108379. Epub 2007 Sep 17.
BACKGROUND/AIMS: Benzodiazepines (BZDs) are the most effective of the psychotropic drugs in the treatment of anxiety disorders. Tolerance has been reported for the majority of BZDs after chronic administration. However, little attention has been paid to the possibility that tolerance might be present after the intermittent oral administration of BZDs. The objectives of the present study were to assess tolerance development after the administration of two intermittent single oral doses of alprazolam given 15 days apart in healthy volunteers, and to compare the results obtained using measures from different domains: neurophysiological, psychomotor and subjective.
Twenty-four healthy volunteers received 2 mg of alprazolam orally on two experimental days, 15 days apart. Plasma concentrations and pharmacodynamics (PD) were assessed before drug intake and at different times in the following 24 h. PD was assessed through EEG (relative alpha and relative beta-1 activities), cancellation task (total and correct number of responses) and visual analogue scales (activity and drowsiness).
No differences were observed in the PKs of alprazolam between occasions. A proteresis was present in both administrations for impairments of psychomotor performance and relative beta-1 activity, whereas it was present only after the second administration for subjective assessments and relative alpha activity. The proteresis on the second occasion was higher than on the first one.
The administration of two single oral doses of alprazolam, 2 weeks apart in healthy volunteers, yielded the same PKs on both occasions, but significant changes were observed in the PD profile. Acute tolerance was observed after the second administration. Two patterns of acute tolerance development were obtained: (1) impairments of psychomotor performance and relative beta-1 activity, and (2) subjective assessments and relative alpha activity.
背景/目的:苯二氮䓬类药物(BZDs)是治疗焦虑症最有效的精神药物。据报道,大多数BZDs长期给药后会产生耐受性。然而,对于BZDs间歇口服后可能出现耐受性的可能性,人们关注较少。本研究的目的是评估健康志愿者间隔15天给予两次间歇单剂量阿普唑仑后的耐受性发展情况,并比较使用不同领域测量方法(神经生理学、精神运动学和主观感受)所获得的结果。
24名健康志愿者在两个实验日口服2mg阿普唑仑,间隔15天。在服药前及服药后24小时内的不同时间点评估血浆浓度和药效学(PD)。通过脑电图(相对α和相对β-1活动)、划消任务(反应总数和正确反应数)和视觉模拟量表(活动和嗜睡程度)评估PD。
两次给药时阿普唑仑的药代动力学未观察到差异。在两次给药中均出现了精神运动性能和相对β-1活动受损的快速耐受现象,而主观评估和相对α活动的快速耐受现象仅在第二次给药后出现。第二次给药时的快速耐受程度高于第一次。
在健康志愿者中,间隔2周给予两次单剂量阿普唑仑口服,两次给药时的药代动力学相同,但药效学特征观察到显著变化。第二次给药后观察到急性耐受性。获得了两种急性耐受性发展模式:(1)精神运动性能和相对β-1活动受损,(2)主观评估和相对α活动受损。